Abstract
BackgroundTo compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice.MethodsThis was a retrospective study. Among 62 Chinese patients with DME, 32 patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a month for 3 months followed by as needed therapy. All participants had at least 12 months of follow-up. We compared the changes in best-corrected visual acuity (BCVA) letter score and central retinal thickness (CRT) between groups, as well as the number of intravitreal injections delivered. Safety was assessed with the incidence of adverse events (AEs).ResultsAt month 12, the mean BCVA letter score improved by 9.3 ± 5.2 with conbercept, and by 8.9 ± 4.4 with ranibizumab, the mean CRT reduction was 138.4 ± 97.7 μm and 145.2 ± 72.5 μm, respectively. There was no statistically significant difference of improvement in BCVA (P = 0.756) and decrease in CRT (P = 0.748) between the two groups. The number of intravitreal injections delivered was significantly higher (P = 0.027) in the IVR group (7.2 ± 1.0 per eye) than in the IVC group (6.6 ± 0.9 per eye). There were no severe ocular adverse reactions or systemic adverse events.ConclusionsBoth conbercept and ranibizumab are effective in the treatment of DME, achieving the similar clinical efficacy. In comparison to ranibizumab, conbercept shows a longer treatment interval and fewer intravitreal conbercept injections are needed.
Highlights
To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice
We reviewed the medical records of all patients with center-involved DME, who received initial injection of conbercept or ranibizumab between 01.05.2014 and 30.09.2015, and had at least 12 months of follow-up
All eyes included in the study should have a central retinal thickness (CRT) ≥ 300 μm measured by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA) letter score between 78 and 24 measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol
Summary
To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. DME may lead to vision loss and blindness, causing significant burdens to the individuals and the society [3]. It arises from the accumulation of plasma constituents and extracellular fluid, as a result of the breakdown of blood-retina barrier [4, 5]. Several studies have reported that anti-VEGF agents (ranibizumab, bevacizumab and aflibercept) are efficacious in the treatment of DME [9,10,11,12,13,14]. The RISE and RIDE studies have demonstrated that intravitreal ranibizumab injections were effective in improving visual acuity in patients with DME [10, 11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
